Leiden, The Netherlands, October 18, 2006 - Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) has announced that its Chief Financial Officer, Leonard Kruimer, will present at the Sanders Morris Harris Middle Market Investor Growth Conference to be held next week (October 23-24) at the Omni Berkshire Place Hotel, New York. 

 

Mr Kruimer will present on Monday, October 23 at 15:00 pm Eastern Time. A live webcast will be available during the presentation at http://www.wsw.com/webcast/smh3/crxl/ and will be available for replay shortly afterwards.

 

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Korea and the US. The Company employs about 900 people. For more information, please visit www.crucell.com.